BBB Strategic Visikol’s focus on blood brain barrier (BBB) assays and models presents a strong cross-sell opportunity for HUREL to expand into CNS-targeted research services, leveraging existing BBB capabilities to attract neuroscience and neuropharmacology clients.

Imaging & GLP The recent launch of multiplex imaging services in a GLP setting signals readiness for regulated, high-throughput tissue analysis; this can be pitched to contract research organizations and pharma sponsors seeking validated imaging workflows.

Tissue Model Suite Visikol offers precision cut tissue slice models including kidney and liver; targeting pharma and biotech customers needing organ-specific preclinical platforms could open new contracts for toxicity, metabolism, and efficacy studies.

Strategic Partnerships Ongoing collaborations with Standard BioTools and related imaging technology partners indicate a strong vendor ecosystem; prospected clients may value bundled solutions combining hardware, imaging, and tissue models for end-to-end studies.

Growth Potential With revenue in the mid single digits and a funding runway, there is capacity for scaled service offerings and tiered pricing for mid-market biotech firms seeking specialized 3D culture and imaging services, suggesting approachable entry points for new clients.